A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer

被引:48
作者
Pantuck, A. J. [1 ]
Pettaway, C. A. [2 ]
Dreicer, R. [3 ]
Corman, J. [4 ]
Katz, A. [5 ]
Ho, A. [5 ]
Aronson, W. [1 ,6 ]
Clark, W. [7 ]
Simmons, G. [8 ]
Heber, D. [1 ,9 ]
机构
[1] Univ Calif Los Angeles, Dept Urol, Inst Urol Oncol, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA
[5] Winthrop Univ Hosp, Garden City, NY USA
[6] VA Med Ctr Greater Los Angeles Healthcare Syst, Los Angeles, CA USA
[7] Alaska Clin Res Ctr, Anchorage, AK USA
[8] Five Valleys Urol, Missoula, MT USA
[9] Univ Calif Los Angeles, Dept Med & Clin Nutr, David Geffen Sch Med, Los Angeles, CA 90095 USA
关键词
MANGANESE SUPEROXIDE-DISMUTASE; FACTOR-KAPPA-B; BIOCHEMICAL RECURRENCE; RADICAL PROSTATECTOMY; PHASE-II; GROWTH; CARCINOGENESIS; RADIATION; JUICE; RISK;
D O I
10.1038/pcan.2015.32
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: The primary objective of this study was to compare the effects of pomegranate juice on PSA doubling times (PSADT) in subjects with rising PSA levels after primary therapy for prostate cancer. METHODS: Double-blind, placebo-controlled multi-institutional study, evaluated the effects of pomegranate liquid extract on serum PSA levels. The primary end point of this study was change in serum PSADT. Additional secondary and exploratory objectives were to evaluate the safety of pomegranate juice and to determine the interaction of manganese superoxide dismutase (MnSOD) AA genotype and pomegranate treatment on PSADT. RESULTS: One-hundred eighty-three eligible subjects were randomly assigned to the active and placebo groups with a ratio of 2: 1 (extract N = 102; placebo N = 64; juice N = 17). The majority of adverse events were of moderate or mild grade. Median PSADT increased from 11.1 months at baseline to 15.6 months in the placebo group (P < 0.001) compared with an increase from 12.9 months at baseline to 14.5 months in the extract group (P = 0.13) and an increase from 12.7 at baseline to 20.3 in the juice group (P = 0.004). However, none of these changes were statistically significant between the three groups (P > 0.05). Placebo AA patients experienced a 1.8 month change in median PSADT from 10.9 months at baseline to 12.7 months (P = 0.22), while extract patients experienced a 12 month change in median PSADT from 13.6 at baseline to 25.6 months (P = 0.03). CONCLUSIONS: Compared with placebo, pomegranate extract did not significantly prolong PSADT in prostate cancer patients with rising PSA after primary therapy. A significant prolongation in PSADT was observed in both the treatment and placebo arms. Men with the MnSOD AA genotype may represent a group that is more sensitive to the antiproliferative effects of pomegranate on PSADT; however, this finding requires prospective hypothesis testing and validation.
引用
收藏
页码:242 / 248
页数:7
相关论文
共 36 条
[1]   Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model [J].
Adhami, Vaqar Mustafa ;
Siddiqui, Imtiaz Ahmad ;
Syed, Deeba N. ;
Lall, Rahul Kumar ;
Mukhtar, Hasan .
CARCINOGENESIS, 2012, 33 (03) :644-651
[2]   Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells [J].
Albrecht, M ;
Jiang, WG ;
Kumi-Diaka, J ;
Lansky, EP ;
Gommersall, LM ;
Patel, A ;
Mansel, RE ;
Neeman, I ;
Geldof, AA ;
Campbell, MJ .
JOURNAL OF MEDICINAL FOOD, 2004, 7 (03) :274-283
[3]   Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents [J].
Antonarakis, Emmanuel S. ;
Zahurak, Marianna L. ;
Lin, Jianqing ;
Keizman, Daniel ;
Carducci, Michael A. ;
Eisenberger, Mario A. .
CANCER, 2012, 118 (06) :1533-1542
[4]  
Aviram M, 2000, AM J CLIN NUTR, V71, P1062
[5]   Complementary medicine use by men with prostate cancer: a systematic review of prevalence studies [J].
Bishop, F. L. ;
Rea, A. ;
Lewith, H. ;
Chan, Y. K. ;
Saville, J. ;
Prescott, P. ;
von Elm, E. ;
Lewith, G. T. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2011, 14 (01) :1-13
[6]  
Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x
[7]   Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy [J].
D'Amico, AV ;
Moul, JW ;
Carroll, PR ;
Sun, L ;
Lubeck, D ;
Chen, MH .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) :1376-1383
[8]   Inflammation in prostate carcinogenesis [J].
De Marzo, Angelo M. ;
Platz, Elizabeth A. ;
Sutcliffe, Siobhan ;
Xu, Jianfeng ;
Gronberg, Henrik ;
Drake, Charles G. ;
Nakai, Yasutomo ;
Isaacs, William B. ;
Nelson, William G. .
NATURE REVIEWS CANCER, 2007, 7 (04) :256-269
[9]   Activation of nuclear factor-κB in human prostate carcinogenesis and association to biochemical relapse [J].
Domingo-Domenech, J ;
Mellado, B ;
Ferrer, B ;
Truan, D ;
Codony-Servat, J ;
Sauleda, S ;
Alcover, J ;
Campo, E ;
Gascon, P ;
Rovira, A ;
Ross, JS ;
Fernández, PL ;
Albanell, J .
BRITISH JOURNAL OF CANCER, 2005, 93 (11) :1285-1294
[10]   Nuclear factor-κB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer [J].
Fradet, V ;
Lessard, L ;
Bégin, LR ;
Karakiewicz, P ;
Masson, AMM ;
Saad, F .
CLINICAL CANCER RESEARCH, 2004, 10 (24) :8460-8464